Live Tumor Board! Experts Navigate the Impact of Neutropenia Across Tumor Types

Release Date: June 29, 2021
Expiration Date: June 29, 2022

Activity Overview

This online, on-demand virtual symposium brings together renowned international experts from several fields of cancer care clinical research to discuss the challenges associated with management of neutropenia. In this educational program, didactic and case presentations will investigate the use of prophylactic growth factors (granulocyte colony-stimulating factors; G-CSF) and biosimilars in patients receiving induction chemotherapy regimens that convey high risk for developing febrile neutropenia. Expert analyses will include a look at both the benefits and limitations associated with approved strategies. This activity will also include a comprehensive discussion of recent data from clinical trials of emerging agents in this space that aim to address unmet needs in cancer patients, including common quality of life issues, such as bone pain, that can arise from G-CSF regimens.

This educational activity is an archive of the live virtual webcast held on June 7, 2021.

Acknowledgement of Commercial Support

This activity is supported by educational grant from BeyondSpring Pharmaceuticals, Inc.

Target Audience

This educational activity is directed toward medical oncologists, hematologists, fellows, surgical oncologists, and radiation oncologists interested in treatment of patients with cancer. Nurse practitioners, nurses, physician assistants, researchers, and other health care professionals interested in the treatment of cancer may also participate.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Evaluate patient-, disease-, and treatment-specific characteristics used to stratify risk level for neutropenia and febrile neutropenia development during cancer treatment
• Discuss the impact of CIN and unmet clinical needs in the management of neutropenia and role of emerging therapies to improve quality of life across tumor settings
• Assess the efficacy and safety profiles of emerging therapeutics evaluated for the management of neutropenia across tumor types
• Apply evidence from landmark trials to develop proactive management plans for real-world case scenarios in the treatment of neutropenia

Faculty, Staff, and Planners’ Disclosures

The staff of Physicians’ Education Resource^®, LLC have no relevant financial relationships with ineligible entities.

Program Chair

Douglas W. Blayney, MD
Professor of Medicine (Oncology)
Stanford University School of Medicine
Associate Division Chief of Medical Oncology
Stanford Health Care
Stanford, CA

Disclosures: Grant/Research Support: BeyondSpring.

Faculty

Gary H. Lyman, MD, MPH, FASCO, FACP, FRCP
Professor, Public Health Sciences and Clinical Research Divisions
Fred Hutchinson Cancer Research Center
Professor of Medicine, Public Health, and Pharmacy
University of Washington School of Medicine
Seattle, WA

Disclosures: Grant/Research Support: Amgen; Consultant: BeyondSpring, Bristol Myers Squibb, G1 Therapeutics, Pfizer, Samsung, Teva.

Jyoti Malhotra, MD, MPH
Assistant Professor of Medicine
Robert Wood Johnson Medical School
Rutgers Cancer Institute of New Jersey
New Brunswick, NJ

Disclosures: Grant/Research Support: BeyondSpring, Biohaven, Bristol Myers Squibb, Celldex, Daiichi Sankyo; Consultant: AstraZeneca, BeiGene, Blueprint Medicines.

Beth Sandy, MSN, CRNP
Thoracic Oncology Nurse Practitioner
Abramson Cancer Center
Hospital of the University of Pennsylvania
Philadelphia, PA

Disclosures: Consultant: AstraZeneca, Jazz Pharmaceuticals, Merck, Takeda.

PER^® mitigated all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.